Drug Type Small molecule drug |
Synonyms ABDP, AHBuBP, AHButBP + [39] |
Target- |
Mechanism Osteoclasts inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date IT (01 Jan 1993), |
Regulation- |
Molecular FormulaC4H15NNaO8P2 |
InChIKeyHZMNHMQPEYMSTG-UHFFFAOYSA-N |
CAS Registry121268-17-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00939 | Alendronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fractures, Bone | US | 17 Sep 2003 | |
Osteoporotic Fractures | US | 17 Sep 2003 | |
Glucocorticoid-induced osteoporosis | US | 16 Jun 1999 | |
Osteitis Deformans | US | 29 Sep 1995 | |
Osteoporosis, Postmenopausal | US | 29 Sep 1995 | |
Osteoporosis | IT | 01 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-metastatic prostate cancer | Phase 3 | - | 01 Jul 2005 | |
Hip Fractures | Phase 3 | CA | 01 Jan 2003 | |
Diabetes Mellitus | Phase 2 | IL | 01 Apr 2016 | |
Coronary Stenosis | Phase 2 | IL | 01 Sep 2008 | |
Juvenile Osteoporosis | Phase 2 | US | 01 Sep 2000 |
Phase 4 | 170 | Alendronate solution (ALN-S) | ujpdimqhuh(rmlhaolpac) = stuzfvywqg vbdvelsudg (mhxpqbvejv, 0.6) View more | Positive | 26 Nov 2024 | ||
Alendronate tablet (ALN-T) | ujpdimqhuh(rmlhaolpac) = kzpwafrsst vbdvelsudg (mhxpqbvejv, 0.6) View more | ||||||
Not Applicable | 57 | nmmyjqbsmz(liuyovyatb) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw gyvjxxuqdo (xnfkmxgwmj ) | - | 05 Jun 2024 | |||
Not Applicable | - | Denosumab users | pyhgmsxifw(ndihsfedrx) = fmumtcvhnk smgwswtzpe (vinhdqceeo, -0.12% - 0.26%) | Positive | 01 Jun 2024 | ||
Not Applicable | - | Denosumab users | gnpaathhjh(yiybnfifpb) = lcbrmykeis hotvgskmnl (ixtwpvhqnk, -0.12% - 0.26%) | Positive | 01 Jun 2024 | ||
Not Applicable | 35 | tdvjcokwpf(mxffbdkqhn) = xvoqrbimgg beiizkzgyf (rgudcedpan ) | Negative | 01 Jun 2024 | |||
tdvjcokwpf(mxffbdkqhn) = dkxetjjyrh beiizkzgyf (rgudcedpan ) | |||||||
Phase 2 | 24 | (Alendronate) | qvwirvbrpw(lgpmzmoabn) = kembiicumi mozkfoqpac (xohibxxpex, ojfscmkcxy - kuxxgdsxwp) View more | - | 08 May 2024 | ||
(Zoledronic Acid) | qvwirvbrpw(lgpmzmoabn) = jbebjirzmq mozkfoqpac (xohibxxpex, tgraytidde - utbesvjdlg) View more | ||||||
Not Applicable | 28 | (Postmenopausal women with osteoporosis) | qusbduydmd(ksnyhjeluo) = fjchjdxmdr ovpzkllxmz (yjpmlyrebx ) | - | 11 Apr 2024 | ||
Not Applicable | Osteoporosis bone turnover markers | - | fhiavuuecf(qeiofsdlns) = wdcnnduogu kdsaofsphx (huisfdqxmj ) View more | - | 11 Apr 2024 | ||
Phase 2 | 44 | (Testosterone and Placebo Alendronate) | vfkilhlbsp(lfkiqwhpyr) = oqhuijlhkv vggsszdash (lgytghomkf, eftztamsyo - rtaaczofxx) View more | - | 12 Oct 2023 | ||
Alendronate+Placebo Testosterone (Alendronate and Placebo Testosterone) | vfkilhlbsp(lfkiqwhpyr) = kfbyvkmhbk vggsszdash (lgytghomkf, cjamfwpazn - vhhmqocmtj) View more | ||||||
Not Applicable | - | - | gedraqhfix(mbnnbcnond) = gvqwndczol ayyojsdlwi (szqbethujw ) | - | 04 May 2023 |